Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04560790
Other study ID # JYMS-CXL#02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 4, 2020
Est. completion date July 5, 2022

Study information

Verified date August 2022
Source Shanghai BDgene Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of BD111 CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy administered via corneal injection in participants with refractory herpetic viral keratitis.


Description:

This is an open-label, single ascending dose study of BD111 in adult (ages 18 to 70) participants with refractory herpetic viral keratitis. Approximately 6 participants will be enrolled.BD111 is a novel gene editing product designed to clear Herpes simplex virus type I (HSV-1) that results in herpetic stromal keratitis in both acute and recurrent infection models which is the leading factor for infectious blindness. The follow-up period was 360 days, and the patients will be followed up 3±1 days, 7±2 days, 30±7 days, 90±14 days, 180±21 days, and 360+31 days after treatment.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date July 5, 2022
Est. primary completion date July 5, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: Patients (replase) with refractory keratitis caused by herpes virus type I who has had at least one time failed corneal transplant. 1. Age between 18 to 70 years. 2. No systemic immune eye disease. 3. Good eyelid structure and blink function. 4. Exists the potential of visual recovery by evaluation of ocular structure and function. 5. Patients with refractory keratitis who are repeatedly infected with HSV-1 virus (more than three times per year) and resistant to topical or systemic anti-viral agents, with no response to regular immunosuppressive agents. 6. Patients who are obviously suffering from relapse HSV infections with corneal perforation, requiring corneal transplantation; 7. No history of corneal trauma. 8. Subjects or their legal guardians voluntarily participate in this study, sign informed consent, good compliance and cooperation with follow-up visits. Exclusion Criteria: 1. Lacrimal coating and blink function loss. 2. Schirmer's test result is less than 2mm for severe dry eye disease. 3. Pregnant and lactating women (pregnancy defined in this study as positive urine pregnancy test). 4. Currently is involved in clinical trials of other drugs or medical devices. 5. Active eye infection (including but not limited to: blepharitis, infectious conjunctivitis, keratitis, sclerotitis, endophthalmitis) in target eye or contralateral eye within 30 days prior to enrollment. 6. Ocular surface malignant tumor. 7. A history of allergic reaction or allergy to sodium luciferin, allergy to protein products used for treatment or diagnosis, allergy to = 2 drugs or non-drug factors, or current allergic disease. 8. current in an infectious disease requiring oral, intramuscular or intravenous administration. 9. Patients with systemic immune diseases. 10. Any uncontrolled clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant neoplasms). 11. Not effective contraception. 12. In uncontrolled hypertension, systolic is no less than 160 mmhg, diastolic is no less than 100 mmhg. 13. In uncontrolled diabetes, fasting glucose is no less than 10.0umol/L. 14. Renal insufficiency, serum creatinine is more than 133umol/L. 15. Arrhythmia, myocardial ischemia, myocardial infarction (diagnosed by electrocardiogram). 16. Liver dysfunction, al ANINE aminotransferase and aspartate aminotransferase levels are higher than 80 IU/L. 17. Platelet level is below 100,000 /uL or above 450,000 /uL. 18. Hemoglobin level is below 10.0g/dL (male) or 9.0g/dL (female). 19. No anticoagulant was used, prothrombin time is higher than 16s, and thrombin time of activated part is higher than 50s. 20. HIV infection (HIV-positive). 21. Subjects lack compliance with the study or the ability to sign informed consent. 22. There are currently signs of systemic infection, including fever and ongoing antibiotic treatment (in this study, systemic infection was defined as deviation from normal values of white blood cells, lymphocytes, and neutrophils on routine blood tests). 23. Administration of Glucocorticoids and other systemic immunosuppressive drugs. 24. The investigator judges other conditions unsuitable for the trial

Study Design


Intervention

Drug:
BD111 Adult single group Dose
3-6 Participants will receive a single group dose administered via corneal injection in the study eye.

Locations

Country Name City State
China Eye & Ent Hospital of Fudan University Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Shanghai BDgene Co., Ltd. Eye & ENT Hospital of Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effective clearance of HSV-1 genome Judge HSV-1 genome clearance effective according to DNA sequencing results by methods of Plaque assay,Elisa,PCR etc. 12 months
Primary Rate of reblindness in 3 participants with Refractory HSV Keratitis 180 days after corneal surgical, calculate rate of reblindness of treated eye in 3 participants. 12 months
Primary HSV-1 virus testing outcome of the intervention eye Herpes virus content before and after treatment were determinated by methods of plaque assay, ELISA, PCR etc. Compare the viral content changes with baseline. 12 months
Secondary Corneal graft survival time Observe the survival time of grafted cornea in participants, whether the grafted cornea is transparency or opacity. 12 months
Secondary Visual improvement compared with baseline Judge the visual recovery progress according to visual examination results on day 3±1,7±2,30±7,90±14,180±21,360±31. 12 months
Secondary Concentration of dose limiting toxicities Observe and record AE,SAE incidence of dose limiting toxicities related with BD111 administration. 12 months
Secondary Concentration of maximum tolerated dose Observe and record AE,SAE at maximum tolerated dose when occurs dose limiting toxicities. 12 months
See also
  Status Clinical Trial Phase
Terminated NCT03674892 - Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain N/A
Recruiting NCT04439552 - fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
Not yet recruiting NCT04122651 - Toric Intraocular Lenses for Cataract Patients in the NHS N/A
Recruiting NCT03299530 - Accuracy of Corneal Astigmatism in Different Region Modes
Recruiting NCT03010748 - Multi-center Clinical Trial on Corneal Morphology Analysis in Chinese Population
Completed NCT02293122 - To Investigate Agreement Between the EM-3000 and the Predicate Device Noncon Robo Pachy (F&A) (CellChek XL)
Active, not recruiting NCT06389916 - Euclid Phoenix Lens Design Trial N/A
Completed NCT06353776 - MicroPulse Transscleral Laser Therapy and Its Short-term Impact on Ocular Surface N/A
Completed NCT03906513 - Evaluation of the Efficacy of OMK2 in Recovering Corneal Neural Damage in Patients With Diabetes N/A
Not yet recruiting NCT06392607 - Euclid Phoenix Lens Design Trial 2 N/A
Recruiting NCT05232539 - Efficiency of Intraoperative Optical Coherence Tomography (iOCT) N/A
Completed NCT02781948 - Evaluation of the Repeatability and Reproducibility of Corneal Epithelial Thickness Mapping With iVue SD-OCT N/A
Not yet recruiting NCT05345652 - Evaluation Of Deep Anterior Lamellar Keratoplasty By Anterior Segment Ocular Coherence Tomography
Completed NCT04804592 - Investigation in Corneal Sensation and Contact Lens Wear N/A
Recruiting NCT04626583 - Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells Phase 1
Recruiting NCT04323358 - Agreement and Accuracy of Different Devices for Biometry Measurements in Patients With Cataract N/A
Completed NCT06277349 - Multifocal-toric IOL Compared to Multifocal IOL Combined With Limbal Relaxing Incisions for Correction of Moderate Astigmatism During Cataract Surgery N/A
Withdrawn NCT02395952 - Healing of Persistent Epithelial Defects N/A
Completed NCT03518775 - Repeatability and Reproducibility of the IOLMaster 700 Vers 1.70 and Agreement With IOLMaster 700 Vers. 1.50 and Pentacam
Terminated NCT04969406 - A Prospective Trial of the Intelon BOSS(TM) System N/A